Compounds > deoxynyboquinone
Page last updated: 2024-12-08

deoxynyboquinone

Description

deoxynyboquinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID295934
CHEMBL ID1972926
SCHEMBL ID14873825
MeSH IDM0547925

Synonyms (19)

Synonym
8-hydroxy-1,4,6-trimethylpyrido[3,2-g]quinoline-2,5,10(1h)-trione
{pyrido[3,2-g]quinoline-2,5,8,10(1h,9h)-tetrone,} 1,4,6-trimethyl-
8-hydroxy-1,4,6-trimethyl-pyrido[3,2-g]quinoline-2,5,10-trione
pyrido[3,5,8,10(1h,9h)-tetrone, 1,4,6-trimethyl-
nsc165572
nsc-165572
NCI60_001271
1,4,6-trimethyl-9h-pyrido[3,2-g]quinoline-2,5,8,10-tetrone
SCHEMBL14873825
CHEMBL1972926
deoxynyboquinone
96748-86-6
AKOS027324995
1,4,6-trimethylpyrido[3,2-g]quinoline-2,5,8,10(1h,9h)-tetrone
MS-24042
1,4,6-trimethylpyrido[3,2-g]quinoline-2,5,8,10(1h,9h)-tetraone
deoxynyboqionone
HY-108992
CS-0033907

Research Excerpts

Overview

Deoxynyboquinone (DNQ) is a potent antineoplastic agent with an unknown mechanism of action.

ExcerptReferenceRelevance
"Deoxynyboquinone (DNQ) is a potent antineoplastic agent with an unknown mechanism of action. "( Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death.
Bair, JS; Hergenrother, PJ; Palchaudhuri, R, 2010)		2.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1617942Antibacterial activity against Bacillus subtilis ATCC 6633 after 16 to 48 hrs2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1617944Antibacterial activity against Escherichia coli ATCC 12435 after 16 to 48 hrs2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1617947Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by alamar blue assay2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1617941Antibacterial activity against Micrococcus luteus ATCC 15307 after 16 to 48 hrs2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1617940Antibacterial activity against Staphylococcus aureus ATCC 6538 after 16 to 48 hrs2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1617945Antibacterial activity against Salmonella enterica ATCC 10708 after 16 to 48 hrs2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1617943Antibacterial activity against Mycobacterium aurum ATCC 23366 after 16 to 48 hrs2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1424115Antibacterial activity against Bacillus thuringiensis SCSIO BT012017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
AID1424144Antibacterial activity against Enterococcus faecalis ATCC 292122017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
AID1617946Antifungal activity against Saccharomyces cerevisiae ATCC 204508 after 16 to 48 hrs2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1424102Antibacterial activity against Staphylococcus aureus ATCC 292132017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
AID1617948Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by alamar blue assay2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
AID1617951Inhibition of 4E-BP1 phosphorylation in human HCT116 cells at 1 uM after 6 hrs by Western blot analysis2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure Determination, Functional Characterization, and Biosynthetic Implications of Nybomycin Metabolites from a Mining Reclamation Site-Associated
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.41 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index5.53 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
beta-lapachone
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.		3.0240benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
nalidixic acid
[no description available]		3.25101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.2110kanamycinsbacterial metabolite
egtazic acid
Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.		2.0710diether;
tertiary amino compound;
tetracarboxylic acid		chelator
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		3.6820beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
lauric acid diethanolamide
lauric acid diethanolamide: component of shampoo implicated in contact dermatitis		3.2510fatty amide
nybomycin
nybomycin: antibiotic substance produced by Streptomyces A 717; structure		2.2110
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		3.6820actinomycinmutagen
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester
[no description available]		2.0710
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		3.0240
5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione
5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione: structure in first source		2.1510
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.2110antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
menaquinone 6
menaquinone 6: RN given refers to (all-E)-isomer		2.0810
vitamin mk 8
vitamin MK 8: isoprenoid acetone-soluble lipid. menaquinone-8 : A menaquinone whose side-chain contains 8 isoprene units in an all-trans-configuration.		2.0810menaquinoneEscherichia coli metabolite;
human metabolite
beta-rubromycin
beta-rubromycin: structure given in first source		2.2110
piericidin a
piericidin A: pyridine-substituted fatty alcohol antibiotic; minor descriptor (75-85); on-line & Index Medicus search ANTIBIOTICS (75-85); RN given refers to (S-(R*,R*-(all-E)))-isomer. piericidin A : A member of the class of monohydroxypyridines that acts as an irreversible mitochondrial Complex I inhibitor that strongly associates with ubiquinone binding sites in both mitochondrial and bacterial forms of NADH:ubiquinone oxidoreductase		3.2510aromatic ether;
methylpyridines;
monohydroxypyridine;
secondary allylic alcohol		antimicrobial agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor;
mitochondrial respiratory-chain inhibitor
napyradiomycin a1
napyradiomycin A1: from culture broth Chainia rubra MG802-AF1; structure given in first source		3.2510menaquinones
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		2.0710organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
novobiocin
Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.		3.2510carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols		antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent
tetracycline
Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.		3.2510
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		2.1510hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
ikarugamycin
ikarugamycin: structure given in first source; an antiprotozoal antibiotic isolated from Streptomyces phaeochromogenes ikaruganensis; inhibits the uptake of oxidized LDL in macrophage J774. ikarugamycin : A polyketide macrolactam containing a tetramic acid (pyrrolidine-2,4-dione) ring system. It is isolated from Streptomyces as an antibiotic with antiprotozoal and cytotoxic activities.		3.2510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.2110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
iodinin
iodinin: antibiotic pigment from Chromobacterium iodinum; structure		3.2510
ConditionIndicatedRelationship StrengthStudiesTrials
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.110
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.110
Benign Neoplasms
[description not available]		02.0710
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		02.0710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0710
chemdatabank.com